Infographic: Clinical Experience with Biosimilar Medicines

Translating experience into regulation 1 August 2022 More than 15 years of experience with biosimilar medicines show…
OPEN LETTER Time for a new medicine security contract for… 1 February 2023 The purpose of Medicines for Europe members is to improve…
EMA/HMA share definitive EU-wide position on biosimilar… 19 September 2022 The Biosimilar medicines group, a Medicines for Europe sector group,…
Open Medicines for Europe letter ahead of the Energy Council… 27 September 2022 For the last decade, off-patent medicines, which represent the 70%…